The source of ACE during scar formation is from both bone marrow and skin tissue
Open Access
- 11 May 2018
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 32 (9) , 5199-5208
Abstract
Angiotensin‐converting enzyme (ACE) has been found in the pathogenesis of various fibrosis diseases, and ACE inhibitor (ACEI) may affect wound healing and cutaneous fibrosis. However, there is no scientific evidence as to where the ACE is produced during scar formation. Whether it is from the cutaneous tissue or the bone marrow, or both remains unknown. In this study, we investigated the source of ACE using bone marrow transplantation in genetically modified mice, analyzed the inflammatory milieu and some growth factors in the middle of the wound healing period (4 d after the wound was induced). After having deleted the ACE from bone marrow or skin tissue, the wound/scar width in the low‐ACE groups were narrower than those in wild‐type (WT) controls. Loosely arranged collagen deposition and reduced vessel density were also detected in ACE‐deficient mice. Lower ACE levels during scar formation were also accompanied by lower levels of TGF‐β1. In the middle of the wound healing period, ACE levels affected the inflammatory cells significantly. In the mice with a deficiency in ACE, the expression of TGF‐β1 and TNF‐α decreased, but not that of IL‐4. Our findings indicate that both bone marrow and skin tissue release ACE during scar formation. Deleting either of them can affect the inflammatory cells and growth factors and reduce the expression of TGF‐β1, resulting in a decreased level of scarring.—Fang, Q.‐Q., Wang, X.‐F., Zhao, W.‐Y., Chen, C.‐Y., Zhang, M.‐X., Shi, B.‐H., Zhang, L.‐Y., Tan, W.‐Q. The source of ACE during scar formation is from both bone marrow and skin tissue. FASEB J. 32, 5199–5208 (2018). www.fasebj.orgKeywords
Funding Information
- Ministry of Health and Welfare (81671918, 81372072)
This publication has 36 references indexed in Scilit:
- Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseasesCurrent Opinion in Pharmacology, 2018
- TSG-6 Released from Intradermally Injected Mesenchymal Stem Cells Accelerates Wound Healing and Reduces Tissue Fibrosis in Murine Full-Thickness Skin WoundsJournal of Investigative Dermatology, 2014
- Collagen VII plays a dual role in wound healingJournal of Clinical Investigation, 2013
- A Modern Understanding of the Traditional and Nontraditional Biological Functions of Angiotensin-Converting EnzymePharmacological Reviews, 2013
- Scar Revision ReviewArchives of Facial Plastic Surgery, 2012
- Hepatic Fibrosis and the Renin-Angiotensin SystemAmerican Journal of Therapeutics, 2011
- Strategies for prevention of scars: what can we learn from fetal skin?International Journal of Dermatology, 2010
- Cutaneous tissue angiotensin–converting enzyme may participate in pathologic scar formation in human skinJournal of the American Academy of Dermatology, 2006
- Effects of ACE Inhibition versus Non-ACE Inhibitor Antihypertensive Treatment on Myocardial Fibrosis in Patients with Arterial HypertensionHerz, 2003
- Cellular Distribution of Angiotensin-Converting Enzyme After Myocardial InfarctionHypertension, 1995